Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: J Nucl Med. 2010 Feb 11;51(3):418–426. doi: 10.2967/jnumed.109.071787

Figure 5.

Figure 5

Whole-body SPECT/CT images of B16/F1 flank melanoma-bearing C57 mice at 2 (A) and 24 h (B) post-injection of 37 MBq (1 mCi) of 111In-DOTA-Nle-CycMSHhex. Tumor (T) and kidneys (K) are highlighted with arrows on the images. HPLC profile (C) of radioactive urine sample of a B16/F1 melanoma-bearing C57 mouse at 2 h post-injection of 111In-DOTA-Nle-CycMSHhex. 111In-DOTA-Nle-CycMSHhex remained intact in the urine 2 h post-injection.